Multiple Myeloma Stages 3
Multiple myeloma stages 3 - multiple myeloma stage 3 - Level II or III multiple myeloma is characterized by the amount of cancer in the middle or high in the body. Patients with any stage of multiple myeloma often have complications of bone as a result of their disease and usually experience symptoms that require treatment.
See also: Multiple Myeloma Stages Life ExpectancyMultiple myeloma stage 3 - There are several effective drugs for chemotherapy, which together combined with the new drug, the drug accuracy, and immunotherapy, used as a treatment for the induction of standard-dose patients with multiple myeloma. The main goal of the initial therapy of multiple myeloma is the loss of complete or almost complete cell myeloma in the body. Most patients can expect to achieve this goal with the help of modern methods
Treatment Planning for Multiple Myeloma
Before starting treatment for myeloma multiple your doctor may discuss with you the opportunity to undergo chemotherapy high dose with stem cell transplant autologous (ASCT), the use of stem cells own patients. Most of the clinical studies done over the past two decades have shown that patients who undergo ASKT after they have gained a remission with chemotherapy traditional, better results.It is important to consider the future of ASCT at the time of diagnosis because stem cells must be collected and frozen in the early stages of the disease, although the treatment plan original used ASCT for treatment after a relapse back myeloma.
Multiple myeloma stages 3 - Another reason why it is important to hold this discussion, is the selection of a plan for ASCT determine the chemotherapy drug that will be early treatment. The type of chemotherapy drug known as an agent alkylating such as Alkeran® (melphalan), damage the cell master make collection difficult or not possible. Therefore, patients who choose to collect and store stem cells is often treated with a regime of induction that does not include agents alkylating. Patients who decide to leave the stem cell transplant or who do not become candidates for transplantation stem cells stem because of advanced age or ill health, are often treated with the use of a schema based on the Alkeran®.
Therapy Standard Induction Therapy for Multiple Myeloma
The majority of patients with multiple myeloma II or level III will initially receive treatment with standard chemotherapy. The doctor will increasingly include drugs precision new in order to improve the result. The main goal of early treatment is to cause loss of complete cell myeloma or complete, and this treatment is sometimes called induction therapy. The choice of initial therapy depends on the age of the patient, the availability of high precision which is suitable and the General condition of the whole patient. Patients in good health, regardless of age, are often treated aggressively to produce a complete remission, while patients who are weak get therapy less aggressive at the start of treatment.
This is the way medical describes a cancerous tumor that involves parameters such as size, localization, and incidence of malignant neoplasms. Knowing the stage of myeloma you need to assign the most effective treatment plan.
Staging of myeloma (plasmacytoma) begins with identifying symptoms. Myeloma can be asymptomatic, and symptoms of the disease. Patients who lack any symptoms of blood cancer, usually do not require treatment and may be under active medical supervision. Patients experiencing specific symptoms of the disease are in need of skilled therapy.
Multiple Myeloma Stages 3: Stage III myeloma
An increased number of myeloma cells in the blood, and there is one or more of the following factors:
- Low Hb level;
- High level of calcium in the blood;
- 3 or more area of bone destroyed by the malignant process;
- A high level of monoclonal immunoglobulin in blood/urine.
Stage plasmacytoma international staging system: today, this staging system is used more widely. The international staging system based on data about patients suffering from multiple myeloma received from around the world. Under this system the development of the disease is divided into three stages, each of which is determined by the levels of serum albumin and beta-2-microglobulin (β2M) serum. After receiving the results of the tests, the treating doctor will explain in detail what they mean and what treatment options are available at this stage of the disease.